STE · Q2 2026 Earnings

Narrative arc: Q4 FY2025 defensive, bioprocessing tempered → Q1 FY2026 FX-funded raise, tariff worsened → Q2 FY2026 organic-driven raise, conservatism cracking.

Three quarters ago bioprocessing was being explicitly tempered; this quarter it is the company's fastest-growing segment. In Q4 FY2025 management said "let's take a little more conservative approach on how aggressively some of the bioprocessing is going to recover." Q1 FY2026 called the trajectory "fairly predictable." This quarter Life Sciences printed +12% constant currency organic with capital equipment up 39%, and management noted recovery in bioprocessing as a driver inside AST services as well: "We've continued to see recovery in, you know, bioprocessing, which was a negative drain on us, you know, for some quarters a year or so ago." The progression — temper → predictable → +12% organic print — confirms that the inflection management was protecting against has materialized.

The reshoring narrative has moved from theoretical dismissal to acknowledged tailwind. In Q4 FY2025 management characterized onshoring as "probably the latter…it takes time," effectively waving off the bull case. This quarter the language is materially different: "there is some. It is real. And I do believe we are getting, you know, maybe some benefit from that on the GMP side or, you know, the pharma side of our capital equipment." That is a six-month round-trip from "McKinsey slide" framing to acknowledged real benefit, and it directly underpins the 100bps organic growth raise.

Conservatism is now being acknowledged rather than camouflaged. The CFO described the raise as reflecting "stronger earnings earlier in the year, improvements in working capital, earlier in the year, and a little bit of cautiousness." That is the first time in three quarters management has explicitly signaled embedded conservatism in the guide. Last quarter the Q1 EPS reaffirmation was rationalized via tariffs and benefit costs; this quarter the raise is small relative to the operational beat, and management is openly telegraphing that the back-half guide is set below run-rate.

Capital equipment is shifting from timing wildcard to confidence anchor. Two quarters ago capital equipment was framed as the lumpy variable that prevented management from raising AST. This quarter management leaned on it as evidence of forward visibility: "Capital equipment backlog was up over 50 percent to 114 million... we're sitting on, you know, a huge backlog number right now for over $400 million in healthcare capital. And our order rate remains strong." Total backlog of $541.3M and the framing has flipped from "wait and see" to "we feel pretty good about, you know, the next two quarters."

One genuine moderation: healthcare service growth is being walked down. Management explicitly flagged: "as that has normalized... what we're going to see is a bit of a slowdown from 12%, 13% to something less than that... will slow down the top line a bit." Healthcare service has run +13% for two consecutive quarters; management is telling investors not to extrapolate. This is the only genuinely negative tone shift in an otherwise upgraded narrative.